NCT01333540

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: Theravance Biopharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.

Conditions

• Opioid-induced Constipation (OIC)

Interventions

Type	Name	Description
DRUG	TD-1211	Escalating doses
DRUG	Placebo	Placebo once daily

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-05-01
• Completion: 2012-06-01
• First posted: 2011-04-12
• Last updated: 2021-01-25

Locations

1 site across 1 country: United States